What is the primary strategic rationale behind Boston Scientific's acquisition of Advanced Bionics?

The primary strategic rationale is to significantly expand Boston Scientific's technology portfolio into the rapidly growing market for implantable microelectronic devices. Advanced Bionics' expertise in neuromodulation technology, including neurostimulators, drug pumps, and cochlear implants, complements BSX's existing offerings and positions the company in a high-growth segment of the medical device industry.

How is the acquisition price structured, and what is the total potential cost to Boston Scientific?

The acquisition involves an initial cash payment of approximately $740 million. Additionally, there are substantial earnout payments contingent upon Advanced Bionics achieving specific future performance milestones, primarily related to net sales and profitability across its technology platforms. The total potential cost could exceed the initial $740 million, depending on the success of Advanced Bionics post-acquisition.

What is the expected impact of this acquisition on Boston Scientific's earnings per share (EPS)?

Boston Scientific anticipates the acquisition to be modestly dilutive to its earnings per share. The estimated dilution is approximately $0.04 per share for 2004 and $0.06 per share for 2005. This suggests that while the acquisition is strategically important, it will have a small negative impact on short-term profitability.

What are the key technology areas that Boston Scientific is acquiring through Advanced Bionics?

Boston Scientific is acquiring Advanced Bionics' neuromodulation technologies, which are implantable microelectronic devices. These include neurostimulators (also known as implantable pulse generators), programmable drug pumps, and cochlear implants. These technologies are designed to treat a range of neurological disorders.

BSX 8-K SEC Disclosure

Summary

Boston Scientific Corporation (BSX) announced on June 1, 2004, a definitive merger agreement to acquire Advanced Bionics Corporation for an initial cash payment of approximately $740 million, plus performance-based earnout payments. This strategic acquisition aims to significantly expand BSX's technology portfolio into the rapidly growing market for implantable microelectronic devices, a sector where Advanced Bionics has developed innovative neuromodulation technologies including neurostimulators, drug pumps, and cochlear implants. The acquisition is structured with a substantial earnout mechanism tied to future sales and profitability milestones across Advanced Bionics' four key technology platforms, with bonus payments for aggregate sales and gross margin targets. While the transaction is expected to be modestly dilutive to earnings per share in 2004 and 2005 ($0.04 and $0.06 respectively), it represents a significant move to bolster BSX's presence in a high-growth medical technology area.

Key Highlights

1Boston Scientific (BSX) to acquire privately held Advanced Bionics Corporation.
2Initial cash payment for the acquisition is approximately $740 million.
3Acquisition includes substantial earnout payments tied to future performance milestones.
4Advanced Bionics specializes in implantable microelectronic devices for neurological disorders (neuromodulation).
5Key technologies acquired include neurostimulators, programmable drug pumps, and cochlear implants.
6Expected to be modestly dilutive to EPS by approximately $0.04 in 2004 and $0.06 in 2005.
7Transaction is expected to close shortly after the June 1, 2004 announcement.

BOSTON SCIENTIFIC CORP 8-K Report (Jun 1, 2004)

Summary

Key Highlights

Frequently Asked Questions